Epithelial to Mesenchymal Transition in Human Mesothelial Cells Exposed to Asbestos Fibers: Role of TGF-β as Mediator of Malignant Mesothelioma Development or Metastasis via EMT Event.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
03 Jan 2019
Historique:
received: 01 12 2018
revised: 24 12 2018
accepted: 27 12 2018
entrez: 6 1 2019
pubmed: 6 1 2019
medline: 12 4 2019
Statut: epublish

Résumé

Asbestos exposure increases the risk of asbestosis and malignant mesothelioma (MM). Both fibrosis and cancer have been correlated with the Epithelial to Mesenchymal Transition (EMT)-an event involved in fibrotic development and cancer progression. During EMT, epithelial cells acquire a mesenchymal phenotype by modulating some proteins. Different factors can induce EMT, but Transforming Growth Factor β (TGF-β) plays a crucial role in promoting EMT. In this work, we verified if EMT could be associated with MM development. We explored EMT in human mesothelial cells (MeT-5A) exposed to chrysotile asbestos: we demonstrated that asbestos induces EMT in MeT-5A cells by downregulating epithelial markers E-cadherin, β-catenin, and occludin, and contemporarily, by upregulating mesenchymal markers fibronectin, α-SMA, and vimentin, thus promoting EMT. In these cells, this mechanism is mediated by increased TGF-β secretion, which in turn downregulates E-cadherin and increases fibronectin. These events are reverted in the presence of TGF-β antibody, via a Small Mother Against Decapentaplegic (SMAD)-dependent pathway and its downstream effectors, such as Zinc finger protein SNAI1 (SNAIL-1), Twist-related protein (Twist), and Zinc Finger E-Box Binding Homeobox 1 (ZEB-1), which downregulate the

Identifiants

pubmed: 30609805
pii: ijms20010150
doi: 10.3390/ijms20010150
pmc: PMC6337211
pii:
doi:

Substances chimiques

Antibodies 0
Asbestos, Serpentine 0
Cadherins 0
Fibronectins 0
SNAI1 protein, human 0
Smad Proteins 0
Snail Family Transcription Factors 0
Transforming Growth Factor beta 0
Vimentin 0
ZEB1 protein, human 0
Zinc Finger E-box-Binding Homeobox 1 0
beta Catenin 0
Matrix Metalloproteinase 2 EC 3.4.24.24

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Thorax. 1999 Jul;54(7):638-52
pubmed: 10377212
Biochem Pharmacol. 2000 Oct 15;60(8):1091-9
pubmed: 11007946
Mol Biol Cell. 2001 Jan;12(1):27-36
pubmed: 11160820
Int Immunopharmacol. 2002 Feb;2(2-3):191-200
pubmed: 11811924
J Clin Invest. 2003 Dec;112(12):1776-84
pubmed: 14679171
Mutat Res. 2004 Mar 14;558(1-2):81-92
pubmed: 15036122
Lab Invest. 2004 Aug;84(8):1013-23
pubmed: 15122306
Int J Dev Biol. 2004;48(5-6):365-75
pubmed: 15349812
Nat Cell Biol. 2004 Oct;6(10):931-40
pubmed: 15448698
Cancer Biol Ther. 2006 Sep;5(9):1059-64
pubmed: 16940750
Neurochem Res. 2007 Apr-May;32(4-5):577-95
pubmed: 16944320
Nat Rev Cancer. 2007 Jun;7(6):415-28
pubmed: 17508028
J Immunotoxicol. 2008 Apr;5(2):145-9
pubmed: 18569384
Transl Res. 2009 Apr;153(4):143-52
pubmed: 19304273
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Eur J Cardiothorac Surg. 2010 Mar;37(3):566-72
pubmed: 19781955
Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314-23
pubmed: 19838011
Antioxid Redox Signal. 2010 Jun 15;12(12):1383-430
pubmed: 19903090
Cancer Lett. 2011 Mar 28;302(2):136-43
pubmed: 21300430
Asian Pac J Trop Med. 2011 Dec;4(12):925-30
pubmed: 22118025
Semin Cancer Biol. 2012 Oct;22(5-6):446-54
pubmed: 22548724
J Cell Biochem. 2012 Jul;113(7):2234-47
pubmed: 22573546
APMIS. 2013 Jan;121(1):1-10
pubmed: 23030626
Am J Pathol. 2013 Nov;183(5):1654-66
pubmed: 24160326
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
J Cell Physiol. 2014 Nov;229(11):1647-59
pubmed: 24610459
J Proteome Res. 2014 Jun 6;13(6):2874-86
pubmed: 24766643
Cells. 2014 Oct 15;3(4):981-93
pubmed: 25317929
Int J Oncol. 2014 Dec;45(6):2522-32
pubmed: 25358858
Environ Health Perspect. 2016 Jun;124(6):776-84
pubmed: 26685284
BMC Cancer. 2018 Aug 15;18(1):819
pubmed: 30111297
Int J Mol Sci. 2018 Aug 20;19(8):null
pubmed: 30127261
Int J Mol Sci. 2018 Nov 15;19(11):null
pubmed: 30445777
Semin Cancer Biol. 2018 Nov 16;:null
pubmed: 30453041
Nat Rev Mol Cell Biol. 2018 Nov 20;:null
pubmed: 30459476
Int J Mol Sci. 2018 Nov 20;19(11):null
pubmed: 30463358

Auteurs

Stefano Turini (S)

Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy. stefano.turini@unito.it.

Loredana Bergandi (L)

Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy. loredana.bergandi@unito.it.

Elena Gazzano (E)

Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy. elena.gazzano@unito.it.

Mauro Prato (M)

Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy. mauro.prato@unito.it.

Elisabetta Aldieri (E)

Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy. elisabetta.aldieri@unito.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH